CoChat
Sign Up
Cited by 51Diabetes Treatment and ManagementOvarian function and disordersPharmacology and Obesity Treatment

The DOI matches its Crossref record; 14 of the 16 references it cites were found in a registry or an index.

Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study

Jensterle, Mojca, Ferjan, Simona, Vovk, Andrej, Battelino, Tadej, Rizzo, Manfredi, Janež, Andrej·2021·Diabetes Research and Clinical Practice
DOI 10.1016/j.diabres.2021.108935
Open this paper in CoChat — free account

Abstract

Aim We evaluated the effect of the latest GLP-1 RA semaglutide on tongue fat storage in obese women. Design We conducted a randomized single-blind, pilot study. Methods Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7 ± 5.3 years, body mass index (BMI) 36.1 ± 3.9 kg/m2, mean ± SD) were randomized to semaglutide 1.0 mg or placebo for 16 weeks. We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging. Results Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94 ± 5.51 vs. + 3.12 ± 4.87 cm 3, p = 0.022, and -0.02 ± 0.07 vs. 0.04 ± 0.06, p = 0.010, respectively). Correlation analysis revealed that these reductions were associated with those in body weight, BMI and waist circumference (p = 0.010 for all). Conclusions This is the first study confirming the beneficial effect of semaglutide on tongue structure in obese women with PCOS. Further studies are needed to assess the clinical importance of such findings.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2021.108935

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In one study (n=25), semaglutide 1 mg once weekly compared to placebo over 16 weeks demonstrated greater weight loss with semaglutide (−5.2 kg versus +1.9 kg with placebo).

    “One study (n = 25) compared semaglutide 1 mg OW to placebo over 16 weeks, demonstrating greater weight loss with semaglutide (− 5.2 kg versus + 1.9 kg with placebo) [167].”

    From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [167]

Citations

Cites

Flagged first, then by citations

2 of the 16 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Eyth E, Basit H, Smith CJ. Glucose Tolerance Test. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 [cited 2021 Apr 2]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK532915/

Cited by

Sorted by citations

Related

Metadata

Authors
Jensterle, M., Ferjan, S., Vovk, A., Battelino, T., Rizzo, M., & Janež, A.
Affiliations
  • University of Ljubljana (SI)
  • University of Palermo (IT)
Corresponding author
Janež, Andrej
ORCID
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2021-08
Volume
178
Pages
108935
ISSN
0168-8227 (ISSN-L)
DOI
10.1016/j.diabres.2021.108935
OpenAlex
W3180621562
Cited by
49
References
16
Citations by year
2026: 14 · 2025: 14 · 2024: 12 · 2023: 4 · 2022: 5
FWCI
3.93
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Diabetes Research and Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
Funders
Javna Agencija za Raziskovalno Dejavnost RS (3-0298, 3-0343)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, GLP-1 receptor agonists, tongue volume, obesity, polycystic ovary syndrome, women, body mass index, waist circumference, weight loss
MeSH terms
Semaglutide, Adult, Double-Blind Method, Glucagon-Like Peptides, Female, Humans, Obesity, Pilot Projects, Tongue, Single-Blind Method, Adiposity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review